Screened 2026-09-01 · the tape above runs as of 22:12 UTC · 11 Sep · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its distribution label.
Azenta, Inc. holds its Distribution at $31.57. Consolidating, no directional conviction, held for 9 days.
As held on the ledger · 2026-09-01
Phase
Distribution · caution
Quantitative state
Consolidating, no directional conviction, held for 9 days
Price at the screen
$31.57
Valuation
N/A trailing · 53.74 forward price to earnings
Values screen
PASS· score 70.0
Beta
1.38
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
2.49%
Below 33%
Interest-bearing debt is just 2.5% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
9.79%
Below 33%
Cash held in interest-bearing accounts and securities is 9.8% of assets, under the one-third limit.
Pass
Receivables
20.49%
Below 49%
Money owed to the company is 20.5% of assets, under the 49% limit.
Pass
Revenue purity
3.16%
Below 5%
Only 3.2% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-09-01 screen. The gold marker is the market price at the same screen. The price runs 28.5% above the base estimate.
Third-party analyst targets: 4 covering, consensus Buy. The average target sits +12% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-01 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Sample handler priced far beyond its real worth
Picture a firm that helps labs store and manage millions of biological samples across continents. Azenta does that job, yet the shares sit well above any sensible price. At twenty six dollars the stock carries a forward multiple of forty three times earnings for revenue that is barely growing and profits that remain deep in the red.
The gap to our fair value of seventeen dollars leaves a thirty six percent shortfall with no margin of safety. One percent top line growth and a negative twenty nine percent profit margin do not support the current valuation, even if five analysts still carry buy notes with a twenty eight dollar median target. Ethical screens clear, but that alone does not turn a stretched price into an opportunity.
High multiples on weak returns on equity and thin growth often signal a value trap rather than a bargain. Currency moves and life science spending cycles add further uncertainty. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
AZTA trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-08-22Markup · changed$33.91+29.0%Entry 5
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 29.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 25%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (5 analysts) rates it none, with a mean price target of $26.
2026-07-22Distribution$26.29+16.4%Entry 4
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 16.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 25%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (5 analysts) rates it none, with a mean price target of $26.
2026-07-18Distribution$22.59+0.0%Entry 3
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 25%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (5 analysts) rates it none, with a mean price target of $26.
2026-07-03Distribution$22.59+0.0%Entry 2
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Distribution$22.59Entry 1
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
